Cosmos Health Inc. announced that its C‑Scrub Wash 4% Surgical Hand Disinfectant has achieved EN 12791:2016+A1:2017 certification, the European standard for surgical hand disinfection. The certification was awarded by Quality Assurance & Control Systems Ltd. (QACS), a Greece‑based laboratory, after the product demonstrated effective antimicrobial activity against resident and transient flora on hands.
The 4% Chlorhexidine Digluconate formulation is designed for surgical hand disinfection, offering broad antimicrobial protection and up to six hours of sustained activity. The certification removes a key regulatory barrier and positions the product for entry into hospital, surgical, and institutional healthcare channels, complementing Cosmos Health’s existing retail presence in the United Kingdom.
Greg Siokas, CEO of Cosmos Health, said the certification “represents an important milestone for the company, enhancing the clinical credibility of our C‑Scrub portfolio and supporting expansion into hospital, surgical, and institutional markets worldwide.” He added that the achievement “strengthens our infection control portfolio and opens additional commercial opportunities across international healthcare markets.”
Cosmos Health’s strategy has focused on expanding its product lines and strengthening retail partnerships, particularly in the UK. The recent launch of C‑Scrub Wash 4% through Superdrug and Tesco in February 2026 has already accelerated retail momentum. The EN 12791 certification now provides the clinical validation needed to pursue institutional sales, potentially unlocking a higher‑margin channel and diversifying revenue streams.
The EN 12791 standard simulates practical conditions to assess a product’s ability to reduce microbial flora immediately after application and over a three‑hour period. By meeting this standard, C‑Scrub Wash 4% aligns with the stringent requirements of hospitals and dental institutions, where surgical hand disinfection is medically indicated to prevent hospital‑acquired infections.
The global antiseptic and disinfectant market was valued at USD 29.15 billion in 2022 and is projected to grow, with Germany alone representing a $752.76 million market in 2022. Cosmos Health’s certification positions it to capture a share of this expanding market, reinforcing its goal of becoming a leading provider of infection‑control solutions across both retail and institutional segments.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.